RELEASE: Dragonfly Therapeutics: First Patient in Clinical Trial Evaluating TriNKET®, Conducted by Merck

-Dragonfly Therapeutics Announces First Patient Dosing in Clinical Trial Evaluating TriNKET® Directed to Solid Tumor, Conducted by Merck.

RELEASE: Dragonfly Therapeutics: First Patient in Clinical Trial Evaluating TriNKET®, Conducted by Merck

-Dragonfly Therapeutics Announces First Patient Dosing in Clinical Trial Evaluating TriNKET® Directed to Solid Tumor, Conducted by Merck

Milestone payment to Dragonfly comes with dosing of first patient in Phase 1 clinical trial

WALTHAM, Mass., Nov. 1, 2022 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly"), announced today that the dose has been administered to the first patient in a clinical trial being conducted by Merck, a well-known as an MSD outside the United States and Canada, to evaluate a TriNKET targeting solid tumors developed by Dragonfly. Dragonfly will receive an undisclosed milestone payment triggered by this event.

"In our 1.0 and 2.0 collaborations, Merck has been an extraordinary partner in oncology, immune disorders and other fields," said Bill Haney, co-founder and CEO of Dragonfly Therapeutics. "We are delighted that the first immunotherapy candidate from our initial collaboration has advanced to the clinic, and equally excited about the progress we are making together to bring Dragonfly's TriNKET technology to targets that address other indications."

The companies' collaboration, initially focused on a number of solid tumor targets, began in October 2018. The collaboration was later expanded in 2020 with a multi-target agreement to develop and commercialize additional natural killer ("NK") cell immunotherapies. in oncology, infectious diseases and immunological disorders. Merck licensed this first TriNKET immunotherapy candidate from Dragonfly in November 2020.

About Dragonfly

Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel bispecific antibody technology to harness the body's innate immune system and deliver innovative treatments to patients. Dragonfly has a wealth of proprietary preclinical candidates discovered through its proprietary platform moving into the clinic, as well as productive collaborations with Merck, Abbvie, Gilead and Bristol Myers Squibb in a wide range of disease areas.

For more information visit: www.dragonflytx.com link https://twitter.com/dragonflytx

DRAGONFLY MEDIUM CONTACT: Anne E. Deconinck | anne@dragonflytx.com

logo - link

View original content: enlace

Yorum yapabilmek için üye girişi yapmanız gerekmektedir.

Üye değilseniz hemen üye olun veya giriş yapın.

NEXT NEWS